Partnering Strategy

A key component of Zelos’ corporate strategy is to seek out quality partnerships and collaborations to best ensure the success of its clinical programs and to fully maximize the value of its assets.

As clinical progress continues to be made on the development of ZT-031 [Ostabolin-C™, cyclic PTH-(1-31)] to treat osteoporosis and other bone-related disorders, Zelos is also exploring its options related to partnerships for further development and commercialization of the lead product candidate.

All Business Development inquiries should be addressed to:

Joseph S. “Jay” Mohr
Chief Business Officer and Acting Head of Finance
Zelos Therapeutics, Inc.
One Tower Bridge
100 Front Street, Suite 1325
West Conshohocken, PA  19428
Telephone:  (610) 825-4547